Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Braz J Med Biol Res ; 57: e13116, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39383377

RESUMEN

Nephrotoxicity is a common complication that limits the clinical utility of cisplatin. Ferroptosis is an iron-dependent necrotic cell death program that is mediated by phospholipid peroxidation. The molecular mechanisms that disrupt iron homeostasis and lead to ferroptosis are yet to be elucidated. In this study, we aimed to investigate the involvement of nuclear receptor coactivator 4 (NCOA4), a selective cargo receptor that mediates ferroptosis and autophagic degradation of ferritin in nephrotoxicity. Adult male Sprague-Dawley rats were randomly-assigned to four groups: control group, cisplatin (Cis)-treated group, deferiprone (DEF)-treated group, and Cis+DEF co-treated group. Serum, urine, and kidneys were isolated to perform biochemical, morphometric, and immunohistochemical analysis. Iron accumulation was found to predispose to ferroptotic damage of the renal tubular cells. Treatment with deferiprone highlights the role of ferroptosis in nephrotoxicity. Upregulation of NCOA4 in parallel with low ferritin level in renal tissue seems to participate in iron-induced ferroptosis. This study indicated that ferroptosis may participate in cisplatin-induced tubular cell death and nephrotoxicity through iron-mediated lipid peroxidation. Iron dyshomeostasis could be attributed to NCOA4-mediated ferritin degradation.


Asunto(s)
Cisplatino , Ferroptosis , Coactivadores de Receptor Nuclear , Ratas Sprague-Dawley , Transducción de Señal , Animales , Ferroptosis/efectos de los fármacos , Masculino , Cisplatino/toxicidad , Coactivadores de Receptor Nuclear/metabolismo , Transducción de Señal/efectos de los fármacos , Ratas , Deferiprona/farmacología , Sistema de Transporte de Aminoácidos y+/metabolismo , Antineoplásicos , Peroxidación de Lípido/efectos de los fármacos , Hierro/metabolismo , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Ferritinas/metabolismo , Enfermedades Renales/inducido químicamente , Enfermedades Renales/metabolismo , Inmunohistoquímica
2.
Mitochondrion ; 78: 101937, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39004262

RESUMEN

Renal iron overload is a common complication of diabetes that leads to oxidative stress and mitochondrial dysfunction in the kidneys. This study investigated the effects of iron chelation using deferiprone on mitochondrial dysfunction and oxidative stress in the renal cortex of a murine model of type 2 diabetes. Diabetic rats were treated with deferiprone (50 mg/kg BW) for 16 weeks. Our results show that iron chelation with deferiprone significantly increased the nuclear accumulation of Nrf2, a transcription factor that regulates the expression of antioxidant enzymes. This led to enhanced antioxidant capacity, reduced production of reactive oxygen species, and improved mitochondrial bioenergetic function in diabetic rats. However, chronic iron chelation led to altered mitochondrial respiration and increased oxidative stress in non-diabetic rats. In conclusion, our findings suggest that iron chelation with deferiprone protects mitochondrial bioenergetics and mitigates oxidative stress in the renal cortex, involving the NRF2 pathway in type 2 diabetes.


Asunto(s)
Deferiprona , Diabetes Mellitus Experimental , Diabetes Mellitus Tipo 2 , Corteza Renal , Factor 2 Relacionado con NF-E2 , Animales , Masculino , Ratones , Ratas , Antioxidantes/farmacología , Antioxidantes/metabolismo , Deferiprona/farmacología , Deferiprona/uso terapéutico , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Modelos Animales de Enfermedad , Quelantes del Hierro/farmacología , Corteza Renal/metabolismo , Corteza Renal/efectos de los fármacos , Mitocondrias/metabolismo , Mitocondrias/efectos de los fármacos , Factor 2 Relacionado con NF-E2/metabolismo , Estrés Oxidativo/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo
3.
Lett Appl Microbiol ; 76(10)2023 Oct 04.
Artículo en Inglés | MEDLINE | ID: mdl-37791895

RESUMEN

This study evaluated the antibiofilm activity of promethazine, deferiprone, and Manuka honey against Staphylococcus aureus and Pseudomonas aeruginosa in vitro and ex vivo in a wound model on porcine skin. The minimum inhibitory concentrations (MICs) and the effects of the compounds on biofilms were evaluated. Then, counting colony-forming units (CFUs) and confocal microscopy were performed on biofilms cultivated on porcine skin for evaluation of the compounds. For promethazine, MICs ranging from 97.66 to 781.25 µg/ml and minimum biofilm eradication concentration (MBEC) values ranging from 195.31 to 1562.5 µg/ml were found. In addition to reducing the biomass of both species' biofilms. As for deferiprone, the MICs were 512 and >1024 µg/ml, the MBECs were ≥1024 µg/ml, and it reduced the biomass of biofilms. Manuka honey had MICs of 10%-40%, MBECs of 20 to >40% and reduced the biomass of S. aureus biofilms only. Concerning the analyses in the ex vivo model, the compounds reduced (P < .05) CFU counts for both bacterial species, altering the biofilm architecture. The action of the compounds on biofilms in in vitro and ex vivo tests raises the possibility of using them against biofilm-associated wounds. However, further studies are needed to characterize the mechanisms of action and their effectiveness on biofilms in vivo.


Asunto(s)
Miel , Staphylococcus aureus , Animales , Porcinos , Prometazina/farmacología , Deferiprona/farmacología , Biopelículas , Pseudomonas aeruginosa , Antibacterianos/farmacología , Pruebas de Sensibilidad Microbiana
4.
Biofouling ; 39(2): 135-144, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-37013808

RESUMEN

This study evaluated the effect of the iron chelator deferiprone (DFP) on antimicrobial susceptibility and biofilm formation and maintenance by Burkholderia pseudomallei. Planktonic susceptibility to DFP alone and in combination with antibiotics was evaluated by broth microdilution and biofilm metabolic activity was determined with resazurin. DFP minimum inhibitory concentration (MIC) range was 4-64 µg/mL and in combination reduced the MIC for amoxicillin/clavulanate and meropenem. DFP reduced the biomass of biofilms by 21 and 12% at MIC and MIC/2, respectively. As for mature biofilms, DFP reduced the biomass by 47%, 59%, 52% and 30% at 512, 256, 128 and 64 µg/mL, respectively, but did not affect B. pseudomallei biofilm viability nor increased biofilm susceptibility to amoxicillin/clavulanate, meropenem and doxycycline. DFP inhibits planktonic growth and potentiates the effect of ß-lactams against B. pseudomallei in the planktonic state and reduces biofilm formation and the biomass of B. pseudomallei biofilms.


Asunto(s)
Burkholderia pseudomallei , Meropenem/farmacología , Deferiprona/farmacología , Hierro/farmacología , Hierro/metabolismo , Biopelículas , Antibacterianos/farmacología , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Pruebas de Sensibilidad Microbiana , Quelantes del Hierro/farmacología
5.
Biometals ; 31(6): 927-940, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30117045

RESUMEN

Brain-derived neurotrophic factor (BDNF) plays a key role in neural development and physiology, as well as in pathological states. Post-mortem studies demonstrate that BDNF is reduced in the brains of patients affected by neurodegenerative diseases. Iron accumulation has also been associated to the pathogenesis of neurodegenerative diseases. In rats, iron overload induces persistent memory deficits, increases oxidative stress and apoptotic markers, and decreases the expression of the synaptic marker, synaptophysin. Deferiprone (DFP) is an oral iron chelator used for the treatment of systemic iron overload disorders, and has recently been tested for Parkinson's disease. Here, we investigated the effects of iron overload on BDNF levels and on mRNA expression of genes encoding TrkB, p75NTR, catalase (CAT) and NQO1. We also aimed at investigating the effects of DFP on iron-induced impairments. Rats received iron or vehicle at postnatal days 12-14 and when adults, received chronic DFP or water (vehicle). Recognition memory was tested 19 days after the beginning of chelation therapy. BDNF measurements and expression analyses in the hippocampus were performed 24 h after the last day of DFP treatment. DFP restored memory and increased hippocampal BDNF levels, ameliorating iron-induced effects. Iron overload in the neonatal period reduced, while treatment with DFP was able to rescue, the expression of antioxidant enzymes CAT and NQO1.


Asunto(s)
Antioxidantes/farmacología , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Deferiprona/farmacología , Modelos Animales de Enfermedad , Quelantes del Hierro/farmacología , Trastornos de la Memoria/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Animales , Antioxidantes/química , Factor Neurotrófico Derivado del Encéfalo/análisis , Deferiprona/química , Femenino , Hipocampo/efectos de los fármacos , Quelantes del Hierro/química , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA